Sinupret Activates CFTR and TMEM16A-Dependent Transepithelial Chloride Transport and Improves Indicators of Mucociliary Clearance

Shaoyan Zhang1,2, Daniel Skinner1,2, Stephen Bradley Hicks1, Mark O. Bevensee2,3, Eric J. Sorscher2,4, Ahmed Lazrak5, Sadis Matalon5, Carmel M. McNicholas3, Bradford A. Woodworth1,5*

1 Departments of Surgery/Division of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 2 Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 3 Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 4 Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 5 Department of Anesthesiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America

Abstract

Introduction: We have previously demonstrated that Sinupret, an established treatment prescribed widely in Europe for respiratory ailments including rhinosinusitis, promotes transepithelial chloride ($\text{Cl}^-$) secretion in vitro and in vivo. The present study was designed to evaluate other indicators of mucociliary clearance (MCC) including ciliary beat frequency (CBF) and airway surface liquid (ASL) depth, but also investigate the mechanisms that underlie activity of this bioflavonoid.

Methods: Primary murine nasal septal epithelial (MNSE) [wild type (WT) and transgenic CFTR$^{-/-}$], human sinonasal epithelial (HSNE), WT CFTR-expressing CFBE and TMEM16A-expressing HEK cultures were utilized for the present experiments. CBF and ASL depth measurements were performed. Mechanisms underlying transepithelial Cl$^-$ transport were determined using pharmacologic manipulation in Ussing chambers, Fura-2 intracellular calcium ($\text{Ca}^{2+}$), imaging, cAMP signaling, regulatory domain (R-D) phosphorylation of CFTR, and excised inside out and whole cell patch clamp analysis.

Results: Sinupret-mediated $\text{Cl}^-$ secretion [AUC($\mu$A/cm$^2$)] was pronounced in WT MNSE (20.7+/-0.9 vs. 5.6+/-0.9(control), p<0.05), CFTR$^{-/-}$ MNSE (10.1+/-1.0 vs. 0.9+/-0.3(control), p<0.05) and HSNE (20.7+/-0.3 vs. 6.4+/-0.9(control), p<0.05). The formulation activated $\text{Ca}^{2+}$ signaling and TMEM16A channels, but also increased CFTR channel open probability (Po) without stimulating PKA-dependent pathways responsible for phosphorylation of the CFTR R-domain and resultant $\text{Cl}^-$ secretion. Sinupret also enhanced CBF and ASL depth.

Conclusion: Sinupret stimulates CBF, promotes transepithelial Cl$^-$ secretion, and increases ASL depth in a manner likely to enhance MCC. Our findings suggest that direct stimulation of CFTR, together with activation of Ca$^{2+}$-dependent TMEM16A secretion account for the majority of anion transport attributable to Sinupret. These studies provide further rationale for using robust Cl$^-$ secretagoue based therapies as an emerging treatment modality for common respiratory diseases of MCC including acute and chronic bronchitis and CRS.

Introduction

Dysfunctional mucociliary clearance (MCC) is a common pathophysiologic process that underlies inflammation and infection in many airway diseases, including chronic rhinosinusitis (CRS) [1,2]. Transport of the mucus layer within the airway surface liquid (ASL) covering respiratory epithelia is influenced by the transepithelial movement of ions, such as $\text{Cl}^-$, and the rate at which cilia beat. There is recent growing interest in the use of Cl$^-$ secretagogues for therapy of sinus disease (Methods, Kits and Compositions for Affecting Chloride Secretion and Ciliary Beating in the Sinonasal Epithelium) (35 U.S.C. n111(b) and 37 C.F.R n53 (c)) in the United States Patent and Trademark Office. Sadis Matalon is the Principal Investigator of a research grant from GlaxoSmithKline to assess the effectiveness of new antagonists of the TRPA1 channel in chlorine toxicity. There are no further patents, products in development, or marketed products to declare.

Citation: Zhang S, Skinner D, Hicks SB, Bevensee MO, Sorscher EJ, et al. (2014) Sinupret Activates CFTR and TMEM16A-Dependent Transepithelial Chloride Transport and Improves Indicators of Mucociliary Clearance. PLoS ONE 9(8): e104090. doi:10.1371/journal.pone.0104090

Editor: Noam A. Cohen, Hospital of the University of Pennsylvania, United States of America

Received November 26, 2013; Accepted July 10, 2014; Published August 12, 2014

Copyright: © 2014 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was funded by the National Institutes of Health/National Heart, Lung, and Blood Institute (1K08HL107142-04) and Flight Attendant’s Medical Research Institute Young Clinical Scientist Award (072218) to B.A.W.; NIH/NIDDK (5P30DK072482-03) to E.J.S and 2R01HL031197 to SM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: I have read the journal’s policy and have the following conflicts: Bradford Woodworth, MD and Eric Sorscher, MD are inventors and have a pending patent regarding the use of chloride secretagogues for treatment of sinus disease (Methods, Kits and Compositions for Affecting Chloride Secretion and Ciliary Beating in the Sinonasal Epithelium) (35 U.S.C. n111(b) and 37 C.F.R n53 (c)) in the United States Patent and Trademark Office. Sadis Matalon is the Principal Investigator of a research grant from GlaxoSmithKline to assess the effectiveness of new antagonists of the TRPA1 channel in chlorine toxicity. There are no further patents, products in development, or marketed products to declare.

* Email: bwoodwo@hotmail.com
a significant reduction in the rate of MCC. Ongoing drug discovery efforts designed to target CFTR (via high throughput compound library screening) are under development for CF and other lower airway diseases [5]. Enhancing MCC also represents an important therapeutic strategy for patients with active sinus disease (by accelerating clearance of bacterial pathogens), and as a preventative measure among individuals prone to developing recurrent infections (by minimizing the accumulation of inhaled particles, including allergens, pollutants, and debris) [4–6]. CRS is recurrent infections (by minimizing the accumulation of inhaled particles, including allergens, pollutants, and debris) [4–6]. CRS is annual in healthcare expenditures [7,8,9].

Sinupret is a phytopharmaceutical widely utilized for a variety of respiratory ailments including rhinosinusitis and bronchitis. The compound is a mixture derived from parts of five plants (elder flowers, primrose flowers with calyx, common sorrel herb, European vervain herb, and gentian root), and has been shown efficacious in reducing acute symptoms and signs of sinusitis [10]. The mechanisms underlying therapeutic benefit of the compound are presently unknown, but are thought to be derived, at least in part, from flavonoid components (flavonol glycosides and free aglycones) of the formulation. Numerous additional molecules have been identified in Sinupret (e.g., iridoid glycosides, caffeoyl derivatives, phenolic compounds, triterpenes, plastocyanin, and phenylpropanoids), and many other components have yet to be characterized [11].

Several flavonoids have been demonstrated to strongly activate CFTR-mediated Cl− currents [12–14]. Our previous studies have established that Sinupret robustly activates transepithelial Cl− secretion in mice in vitro and in airway epithelial cells in vivo. The purpose of the present study was to determine whether this flavonoid therapeutic activates ciliary beat frequency (CBF) and enhances ASL, and to investigate the underlying mechanism responsible for the Cl− secretagogue activity of Sinupret.

**Materials and Methods**

**Primary Cell Culture**

Institutional Review Board and Institutional Animal Care and Use Committee approval were obtained prior to initiating these studies. MNSE and HSNE cells were harvested, grown on Costar 6.5-mm diameter permeable filter supports (Corning Life Sciences, Lowell, MA), and submerged in culture medium as previously described [15–22]. Media was removed from the monolayers on day 4 after the epithelium reached confluence, and cells fed via the basal chamber. Transgenic CFTRΔF508 MNSE cultures were also investigated to test CFTR-dependent effects and evaluate contributions from the apical calcium-activated Cl− channel, TMEM16A. Differentiation and ciliogenesis occurred in all cultures within 10 to 14 days. Cultures were used for experiments when fully differentiated with widespread ciliogenesis.

A total of 420 MNSE and 48 HSNE cell monolayers were used to complete these experiments. Cultures with transepithelial resistances (Rt) >300 Ω·cm² were used to obtain short-circuit current measurements, monitor ciliary beating by inverted microscopy, and measure ASL depth. A minimum of 5 wells were tested per condition.

**Using Chamber Analysis**

Transwell inserts (Costar) were mounted in Ussing chambers to investigate pharmacologic manipulation of vectorial ion transport as previously described [13,17]. Monolayers were evaluated under short circuit current conditions following fluid resistance compensation using automatic voltage clamping (VCC 600; Physiologic Instruments, San Diego, CA). Serosal bath solutions contained (in mM): 120 NaCl, 25 NaHCO3, 3.3 KH2PO4, 0.8 K2HPO4, 1.2 MgCl2, 1.2 CaCl2, and 10 glucose. Baths for transwell filters were warmed to 37°C and gassed continuously with a 95% O2-5% CO2 mixture that provides a pH of 7.4 under conditions studied here. Chemicals were obtained from Sigma (St. Louis, MO) except for Sinupret which was purchased online (Bionorica, Neumarkt, Germany). Using chamber experiments were performed with a nominal mucosal Cl− in which 6 mM replaced NaCl in the above solution. The following pharmacologic agents were used: amiloride (100 μM) - blocks epithelial Na+ channels, as a means to isolate changes in short-circuit current (ΔISC) secondary to effects on Cl− channel activity [23]; forskolin (20 μM) - activates CFTR by elevating intracellular cAMP, which results in protein kinase A (PKA)-dependent phosphorylation of the CFTR regulatory domain (R-D); tannic acid (100 μM) - an inhibitor of calcium-activated Cl− channels (recently identified as TMEM16A [24]); INH-172 (10 μM) - a CFTR inhibitor that permits determination of CFTR-dependent contributions to ISC [17]; and Sinupret (2.5 mg/ml). Each solution was produced as 1,000× stock and studied at 1× in the Ussing chamber or by CBF analysis. Stock solutions of Sinupret tablets were generated by dissolving in dimethyl sulfoxide (DMSO) followed by removal of insoluble matter by filtration (i.e., concentrations described here do not account for removal of insoluble particulates) [15]. Maximal solubility and activity of the drug was at 2.5 mg/ml with an EC50 of 200 μg/ml. DMSO control solutions were tested for comparison in all cases. The ISC was continuously assessed at one current measurement per second. By convention, a positive deflection in the ISC under conditions tested here was defined as the net movement of anions from the serosal to mucosal direction.

**Detection of Regulatory Domain (R-D) Phosphorylation and cAMP levels**

Cellular cAMP was measured using an ELISA-based detection kit (Cayman Chemicals, Ann Arbor, MI) as previously described [25]. To evaluate R-D phosphorylation, polyclonal NIH-3T3 cells expressing the HA-tagged R-domain were treated with Sinupret solution for 20 minutes, and compared to forskolin (20 μM) ×5 minutes (as a positive control) or DMSO alone (negative vehicle control). Following lysis, equal amounts of protein (50 μg) from total cell lysate were electrophoresed through a 12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE), and immunoblotted with antibody to the HA domain (R-D); tannic acid (100 μM) - an inhibitor of calcium-activated Cl− channels (recently identified as TMEM16A [24]); INH-172 (10 μM) - a CFTR inhibitor that permits determination of CFTR-dependent contributions to ISC [17]; and Sinupret (2.5 mg/ml). Each solution was produced as 1,000× stock and studied at 1× in the Ussing chamber or by CBF analysis. Stock solutions of Sinupret tablets were generated by dissolving in dimethyl sulfoxide (DMSO) followed by removal of insoluble matter by filtration (i.e., concentrations described here do not account for removal of insoluble particulates) [15]. Maximal solubility and activity of the drug was at 2.5 mg/ml with an EC50 of 200 μg/ml. DMSO control solutions were tested for comparison in all cases. The ISC was continuously assessed at one current measurement per second. By convention, a positive deflection in the ISC under conditions tested here was defined as the net movement of anions from the serosal to mucosal direction.

**Fura-2 Imaging**

Changes in cytosolic calcium [Ca2+]i were measured with dual excitation wavelength fluorescence microscopy after cells were loaded with the Ca2+-sensitive dye Fura-2 [26]. HSNE cells were perfused with solutions containing either Sinupret 2.5 mg/ml, DMSO control, or 140 mM UTP (Sigma) as a positive control. Alteration in fluorescence intensity was monitored by a Photon Technology International (Birmingham, NJ) dual wavelength spectrophuorometer (excitation wavelength: 340/380 nm and emission wavelength: 510 nm). The intensity of fluorescence was calculated automatically. The Rmax and Rmin values were determined by the addition of 3 mM Ca2+ and 5 mM EGTA plus 5 μM ionomycin, respectively.
Whole Cell Patch Clamp Analysis

Mouse TMEM16A subclone in frame within the pEGFP-N1 vector was kindly provided by Professor Lily Y. Jan (University of California, San Francisco). The TMEM16A-GFP construct was as described previously by Schroeder et al. [27] HEK 293 cells were transfected using Lipofectamine 2000 Transfection reagent (Life technologies, Cat. No:11668) according to the manufacturer’s instructions. Stably TMEM16A transfected HEK 293 cells were maintained in DMEM supplemented with 10% FBS and 0.4 mg/ml G418 at 37°C in 5% CO2 and passaged every 2–5 d. Cells were split and seeded on glass coverslips one day before whole-cell patch clamp analysis. Each cover slip with cells was transferred to an experimental chamber mounted on the stage of an Olympus microscope. TMEM16A currents were recorded in whole cell mode of the patch clamp technique using an Axopatch 200B amplifier interfaced to a computer through DIGITA 1200 A. The data was recorded and analyzed using Pclamp software (Molecular Devices). During the experiments, cells were perfused with an external solution of the following ionic composition (in mM): 145 CaCl2, 2 MgCl2, 2 CaCl2, 5.5 Glucose, 10 HEPES, pH 7.4 (1 N NaOH). The pipette resistance used for whole recording ranged from 3 to 5 GΩ when filled with the following intrapipette solution (in mM): 135 CsCl, 10 KCl, 2 MgCl2, 0.1 EGTA, 5.5 Glucose, 10 HEPES, pH 7.2 (1N KOH). All experiments were performed at room temperature. Cells were continuously perfused with the external solution until formation of the recording whole cell configuration. Activators and inhibitors of TMEM16A were applied through the same perfusion system. The rate of perfusion was adjusted to 1 ml/min.

Single Channel Studies

Conventional inside out patch clamp recordings were performed using CFBE cells expressing WT CFTR. Recording pipettes were constructed from borosilicate glass capillaries (Warner Instruments, Hamden CT) using a Narishige PP83 microelectrode puller and fire polished with a PP90 microforge (Narishige, Tokyo). The pipettes were partially filled with a solution containing (in mmol/l) 150 CsCl, 1 CaCl2, 1 MgCl2, and 10 HEPES (pH 7.2) and with tip resistances of 6–8 MΩ. Experiments were performed at room temperature (20–22°C). Single channel currents were obtained using an Axopatch 200B patch clamp amplifier (Axon Instruments, CA), Molecular Devices, USA) with voltage commands and data acquisition controlled by Clampex software (pClamp 10, Axon Instruments) and digitized (Digitata 1440A interface, AI) at a sampling frequency of 1 kHz. CFBE cells were seeded on glass coverslips and mounted in a flow through chamber. To obtain seals, bath solutions contained (in mmol/l) 140 NaCl, 4.0 KCl, 1.8 CaCl2, 1.0 MgCl2, 10 glucose, 10 HEPES, pH 7.4. For inside out patches, bath solution contained (in mmol/l) 150 CsCl, 5 EDTA and 10 HEPES pH 7.4 designed to prevent calcium-activated currents. Sinupret was added to the CsCl bath solution and used at a final concentration of 2.5 mg/ml from a 250 mg/ml stock dissolved in DMSO. Vehicle controls were included in all studies [DMSO (0.01%)]. As an additional control, patches were exposed to ATP (1 mM/PKA 40 units/ml) after Sinupret following perfusion if channel activity was not observed. Confirmation that stimulated currents were due to CFTR was achieved using the inhibitor CFTRinh-172 at 10 μM. Single channel recordings were analyzed using pClamp 10 software (AI).

Ciliary Beat Frequency Analysis

Images were visualized using a 20 × objective on an inverted scope (Fisher Scientific, Pittsburgh, Pa.). Data were captured using a Model A602f-2 Basler area scan high-speed monochromatic digital video camera (Basler AG, Ahrensburg, Germany) at a sampling rate of 100 frames per second. Image analysis was performed with the Sisson-Ammons Video Analysis (SAVA) system, version 2.1.6 [20]. For each experiment, a large area of beating cilia within air-liquid interface cultures was identified with the inverted microscope. Images were analyzed with virtual instrumentation software designed specifically for measuring CBF. A baseline recording of CBF was conducted for each cell monolayer prior to applying an apical test solution. All experiments were compared to the corresponding control using vehicle alone (apical fluid addition, by itself, can increase CBF). Each recording was normalized to fold-change over baseline (Hertz pre-to post-treatment). All studies were performed at ambient temperature (25°C).

Airway Surface Liquid Depth

MNSE cells were washed 3 times with PBS, and then exposed to 100 μM CellTracker Green BODIPY (Invitrogen, Cat#: C2102) in differentiation medium from the basolateral side, and 10 mg/ml Texas Red (Invitrogen, Cat #: D-1863) in FC-70 (Flourinert FC-70, Fisher, Cat #: NC 906226) from the apical side. Sinupret (2.5 mg/ml) or the vehicle (DMSO) control was added in a 30 μl volume to the apical and basolateral compartments for 30 minutes. Imaging was performed with a Zeiss LSM 710 Confocal Microscope with a Zeiss Plan Apo 20 ×.8 na Dry Objective in 1 micron steps. ASL depth was measured in the orthogonal (head on X-Z) image view.

Statistical analysis

Statistical analyses were performed using unpaired t tests or analysis of variance with Tukey-Kramer post hoc analysis as appropriate +/- standard deviation. A p value<0.05 was considered statistically significant.

Results

Sinupret increases transepithelial Cl− transport through CFTR and calcium-activated pathways in Ussing chamber analysis

One of the goals of this study was to test whether Sinupret stimulated CFTR or calcium-activated Cl− (TMEM16A) channels on the apical cell surface. The primary method to evaluate anion transport involved pharmacological manipulation of cell cultures maintained in Ussing chambers followed by measurements of short-circuit current (ΔIsc). After blocking epithelial sodium channels with amiloride, Sinupret-dependent ΔIsc (in μA/cm²) was tested in wild type (WT) MNSE (Figure 1A), CFTR−/− MNSE (Figure 1B), and HSNE cultures (Figure 1C). Summary data is presented in Figure 1D. Sinupret significantly increased ΔIsc when compared to vehicle control in WT MNSE (20.7+/-0.9 vs. 5.6+/-0.9, p<0.05). In addition, Sinupret significantly stimulated Cl− secretion in HSNE cultures when compared to DMSO control [ΔIsc, 20.7+/-0.3 vs. 6.4+/-0.9, p<0.05] establishing that the therapeutic is a strong Cl− secretagogue in human sinus and nasal epithelium. The formulation also amplified ΔIsc in CFTR−/− MNSE cultures [ΔIsc, 10.4+/-1.0 vs. 0.9+/-0.3, p<0.05], albeit at levels approximately 30% of WT. These data suggest stimulation of transepithelial Cl− secretion is partially mediated through channels other than CFTR.

Another means to investigate overall contribution of CFTR channel activation to the Sinupret -mediated ΔIsc is by blocking CFTR with the specific inhibitor INH-172 or pre-treating the cells with tannic acid (to eliminate calcium-activated Isc). We observed
Figure 1. Sinupret is a robust activator of CFTR-mediated and calcium-activated Cl− secretion. Representative Ussing chamber tracings demonstrate pharmacologic manipulation of ion transport with activation of Cl− secretion (Agonist = Sinupret or DMSO control vehicle) in murine nasal septal epithelial (MNSE, wild type and CFTR−/−) and human sinonasal epithelial (HSNE) cell cultures following blockade of epithelial sodium channels by amiloride. Strong inhibition of short-circuit current (Isc) by the specific CFTR inhibitor INH-172 indicates activation of CFTR-mediated pathways in WT MNSE (A) and HSNE (B). CFTR−/− MNSE tested with forskolin confirm absence of cAMP-dependent CFTR-dependent transport, but retained strong stimulation of anion secretion by Sinupret (C). Summary data for Sinupret-stimulated ΔIsc in WT MNSE, CFTR−/− MNSE and HSNE (D). Sinupret significantly increased ΔIsc (in μA/cm²) when compared to controls in both WT (20.7+/−0.9 vs. 5.6+/−0.9, p<0.05) and CFTR−/− MNSE (ΔIsc in μA/cm²; 10.1+/−1.0 vs. 0.9+/−0.3, p<0.05). HSNE cultures also exhibited robust Cl− secretion when compared to controls (ΔIsc 20.7+/−0.3 vs. 6.4+/−0.9, p<0.05). There were significant decreases in Isc when cultures were treated with CFTR inhibitor INH-172 in WT MNSE (−16.1+/−1.3 vs. −6.5+/−0.7, p<0.05) and HSNE cells (−17.0+/−1.6 vs. −11.1+/−1.7, p<0.05).

doi:10.1371/journal.pone.0104090.g001

Sinupret stimulates epithelial chloride transport

Sinupret activates Ca2+-mediated, but not cAMP/PKA-dependent cell signaling pathways

CFTR-mediated anion secretion is regulated by cAMP/PKA-dependent second messenger signaling, which results in phosphorylation of the regulatory (R)-domain. TMEM16A-dependent transport relies on fluxes in intracellular Ca2+. In order to determine whether Sinupret works via these second messenger pathways, intracellular Ca2+, cAMP, and a gel shift assay used to detect R-domain phosphorylation were utilized. Sinupret applied to MNSE cultures at 0.1, 1.0, and 2.5 mg/ml did not increase cAMP (in pmol/ml) in contrast to that seen with the positive control 20 μM forskolin (Figure 3A). Additionally, Sinupret did not confer phosphorylation of the CFTR R-domain (Figure 3B). We performed Fura-2 Ca2+ imaging to assess whether the formulation stimulates transport via an increase in [Ca2+], [24]. An increase in [Ca2+]i (in nM) was observed by this assay following treatment with 2.5 mg/ml Sinupret (262.8+/−14.4 vs. 48.3+/−28.5, p<0.05). The Sinupret-induced [Ca2+]i rise was approximately 70% of the UTP-induced [Ca2+]i rise, which served as the positive control (377.8+/−70.3). UTP response following Sinupret (300.7+/−84.1) was not significantly different than UTP alone (Figure 4).

Sinupret activates TMEM16A and increases CFTR channel open time as judged by whole cell and single channel patch clamp analysis

To determine whether TMEM16A was definitively activated by Sinupret, HEK cells stably transfected with TMEM16A were subjected to whole cell patch clamp analysis (Figure 5). Perfusion
with Sinupret induced activation of a Cl⁻ current that was inhibited by tannic acid. DMSO controls had no effect on TMEM16A activity at the cell surface, while positive controls had UTP-dependent activation that was prominently blocked by tannic acid.

Application of 2.5 mg/ml Sinupret resulted in activation of a small conductance Cl⁻ channel consistent with CFTR (with the anticipated single channel conductance and INH-172 sensitivity) in 4 out of 14 inside-out patches from CFBE cells. In 4 experiments, ATP/PKA was added to the bath following Sinupret exposure but with no channel activation. For patches in which Sinupret activated CFTR, NPO increased from 0.77 ± 0.26 to 2.21 ± 0.98—a 2.9 fold increase in activity (NPO/n: 0.18 ± 0.06 to 0.43 ± 0.15, where n = number of discernable channel levels). Thus, in the absence of other stimulatory molecules, Sinupret increased CFTR channel Po. This is consistent with our finding of CFTR activation in an intact cell preparation (Figure 1) in which Sinupret increased CFTR channel activity in the absence of in vitro stimulation by PKA (Figure 3).

Figure 2. Elimination of TMEM16A-mediated lsc with tannic acid suggests Sinupret stimulates CFTR-mediated Cl⁻ transport. Representative Ussing chamber tracings demonstrate administration of the TMEM16A blocker tannic acid abolishes agonist (Sinupret)-stimulated Cl⁻ secretion in CFTR⁻/⁻ cells (A). Pre-treatment of WT MNSE shows persistent activation despite elimination of TMEM16A contributions to the lsc (B). Summary data (C) for Sinupret-stimulated Δlsc in WT MNSE [μA/cm², 12.8+/−2.2 vs. 3.6+/−0.9 (control), p<0.05] following tannic acid block of TMEM16A-mediated lsc and CFTR blockade with INH-172 (−11.5+/−1.7 vs. −9.0+/−1.5, p<0.05).

doi:10.1371/journal.pone.0104090.g002

Figure 3. Activation of chloride secretion occurs through a mechanism independent of PKA and R-Domain phosphorylation of CFTR. MNSE cells were exposed to forskolin (20 μM, positive control, P<0.05), vehicle (DMSO), or graded concentrations of Sinupret for 10 minutes prior to assay. Sinupret did not induce a mean increase in cAMP compared to vehicle control, while forskolin led to a marked elevation of cAMP (A). Sinupret does not induce R-domain phosphorylation (B). The recombinant CFTR R-Domain was expressed in stably transfected NIH-3T3 cells and detected by immunoblotting with an antibody to the HA tag (black arrow). A 2–4 kD mobility shift is indicative of R-Domain phosphorylation (white arrow) following 5 minute treatment with forskolin (20 μM, positive control). Sinupret had no detectable effect on R-domain phosphorylation at a maximum concentration of 2.5 mg/ml.

doi:10.1371/journal.pone.0104090.g003

Application of 2.5 mg/ml Sinupret resulted in activation of a small conductance Cl⁻ channel consistent with CFTR (with the anticipated single channel conductance and INH-172 sensitivity) in 4 out of 14 inside-out patches from CFBE cells. In 4 experiments, ATP/PKA was added to the bath following Sinupret exposure but with no channel activation. For patches in which Sinupret activated CFTR, NPO increased from 0.77 ± 0.26 to 2.21 ± 0.98—a 2.9 fold increase in activity (NPO/n: 0.18 ± 0.06 to 0.43 ± 0.15, where n = number of discernable channel levels). Thus, in the absence of other stimulatory molecules, Sinupret increased CFTR channel Po. This is consistent with our finding of CFTR activation in an intact cell preparation (Figure 1) in which Sinupret increased CFTR channel activity in the absence of in vitro stimulation by PKA (Figure 3).

Sinupret increases CBF in vitro

CBF is an important component of MCC that responds to elevation of intracellular Ca²⁺. To determine whether Sinupret activates CBF, the drug was applied to the apical, basolateral, or apical-basolateral membranes and compared to corresponding vehicle controls. Sinupret elicited a significant increase in the mean CBF (fold-change/baseline) of MNSE cultures when applied to the apical membrane [2.05+/−0.15 vs. 1.52+/−0.10 (control),
Sinupret enhances ASL depth

It is well-established that stimulation of transepithelial Cl⁻ secretion leads to airway surface hydration and promotes ASL depth. In order to evaluate effects of the formulation on ASL, MNSE cultures were exposed to Sinupret and stained to visualize overlying surface liquid. Sinupret significantly increased ASL depth in these cultures (in μm: 9.14 ± 0.42 vs. 5.25 ± 0.38, control, *p<0.05) indicating a vigorous treatment effect (Figure 7).

Discussion

Sinupret has been utilized extensively throughout Europe for more than 70 years as treatment of airway diseases associated with inadequate MCC, and has an excellent safety profile. The medication is registered as a regulated phyto-pharmaceutical in Germany [29], and has been available in the United States for 9 years where it is considered an herbal supplement (not regulated by the Food and Drug Administration) [11]. The drug has been extensively investigated in a variety of scientific studies and clinical settings. Prophylactic administration to mice led to increased resistance against respiratory tract infection following intranasal application of Sendai virus (Parainfluenza viridae) [30]. Mucus clearance properties have been observed in rabbit tracheas [31]. Several clinical trials have tested the effect of Sinupret either alone or in combination with antibiotics for rhinosinusitis. Significant improvement in radiologic outcomes and headache were demonstrated in a randomized, placebo-controlled trial [32]. When used as an adjunctive treatment with antibiotics and/or nasal decongestants in this setting, two clinical studies demonstrated benefit versus placebo [33].

In the present experiments, we establish that Sinupret-stimulates Cl⁻ secretion in part by activating apical CFTR channels. This finding is supported by: 1) a significant decrease in ΔISC with chemical inhibition (INH-172) in WT airway epithelial basalateral membrane [1.37+/−0.09 vs. 0.99+/−0.04(control)], or both [2.17+/−0.12 vs. 1.53+/−0.09(control)] (*p<0.05) (Figure 6).

Figure 4. Sinupret raises cytosolic Ca²⁺ concentrations in human sinonasal epithelium. Representative tracings of Fura-2 Ca²⁺ imaging (A). Stimulation of intracellular Ca²⁺ was demonstrated following the addition of Sinupret to HSNE cells. UTP (positive control) also led to increased intracellular Ca²⁺.

doi:10.1371/journal.pone.0104090.g004

Figure 5. Activation of TMEM16A channels expressed in HEK-293 cells with Sinupret. Control whole cell current was recorded in the presence of DMSO vehicle. DMSO was without any effect on TMEM16A expressed at the surface of HEK cells (A). Perfusion with the solution containing 2.5 mg/ml (B). Sinupret induced the activation of a Cl⁻ current that was inhibited by 200 μM tannic acid (C). IV curves are illustrated during the activation of the Cl⁻ current with Sinupret and inhibition by tannic acid when voltage steps were varied from −80 mV to 100 mV in 20 mV increments for 500 ms (D). The cell membrane potential was held at 0 mV throughout the experiment. Control current recorded before cells were treated with UTP - a known activator of TMEM16A channels (E). TMEM16A response to 200 μM UTP in the perfusing solution (F). Inhibition of the UTP activated current with 200 μM tannic acid (G). IV curves (H) showing the activation of the current at a range of voltage stimulation as in (D).

doi:10.1371/journal.pone.0104090.g005

Figure 6. Stimulation of CBF. CBF (fold-change/baseline) was significantly increased when Sinupret was compared to control (vehicle) following apical (2.05+/−0.15 vs. 1.52+/−0.10), basal (1.37+/−0.09 vs. 0.99+/−0.04), or apical + basolateral exposures (2.17+/−0.12 vs. 1.53+/−0.09), (*p<0.05).

doi:10.1371/journal.pone.0104090.g006
monolayers, 2) stimulation of ICN, despite pretreatment with tannic acid in WT MNSE, 3) blunted Cl\(^-\) secretion in CFTR\(^{-/-}\) MNSE lacking CFTR, and 4) excited inside-out patch clamp analysis demonstrating increase in CFTR channel Po. Overall Cl\(^-\) transport remained significantly greater than controls despite absence of CFTR channel function (Figure 1), suggesting either increased Cl\(^-\) gradient (secretory driving force) due to activation of basolateral \(K^+\) channels (NKCC1) that promote Cl\(^-\), and/or increased gating of TMEM16A was responsible for the residual transepithelial Cl\(^-\) secretion in the absence of CFTR. Notably, Cl\(^-\)-dependent ICN was abrogated following addition of the TMEM16A blocker tannic acid in CFTR\(^{-/-}\) cell monolayers, indicating that non-CFTR activity was responsible for these findings. It has been reported previously that the absence of CFTR in murine airways may confer enhanced expression or activity of other Cl\(^-\) secretory pathways, including TMEM16A [34]. Therefore, the Cl\(^-\) secretory mechanisms available for stimulation in CFTR\(^{-/-}\) mice may differ from those in WT. Nevertheless, Fura2-imaging suggests intracellular Ca\(^{2+}\) release contributes to TMEM16A activation in this setting, while activation of current in whole cell patch clamp analysis in TMEM16A transfected cells confirms these channels are stimulated by Sinupret. Therefore, Cl\(^-\) transport is clearly mediated via effects on both apical CFTR and TMEM16A.

Two key components of MCC include ciliary beat and the composition of the ASL. Because Sinupret stimulates intracellular Ca\(^{2+}\) signaling cascades known to stimulate both TMEM16A-mediated Cl\(^-\) transport and CBF in mammalian respiratory epithelial cells [16,35], it is not surprising that an increase in CBF as well as ASL depth was noted in this study. Stimulation of CFTR-dependent pathways through increased channel Po (as opposed to cAMP/PKA-mediated phosphorylation of the R-domain) may also contribute [36,37] and are likely related to the flavonoid components of the formulation [4,6]. Activation of mechanisms such as these would improve MCC and probably account for underlying health benefits of the drug.

Conclusions

Sinupret likely derives its clinical benefit, at least in part, through stimulating transepithelial Cl\(^-\) secretion, CBF, and MCC. Augmenting fluid and electrolyte secretion represents a means of improving mucus clearance in individuals affected by acute or chronic rhinosinusitis, specifically in the setting of WT CFTR. The present studies also point to molecular pathways that might be targeted as a means to improve therapy of MCC in diseases such as CRS and COPD in the future.

Acknowledgments

Portions of this manuscript were presented at the American Rhinologic Society’s spring meeting, Las Vegas, Nevada, April 29th, 2010

Author Contributions

Conceived and designed the experiments: SZ MOB EJS BAW. Performed the experiments: SZ DS SBH BAW. Analyzed the data: SZ DS SBH BAW. Contributed reagents/materials/analysis tools: MOB EJS BAW AL SM CMM. Wrote the paper: SZ BAW.

References

1. Alexander NS, Blount A, Zhang S, Skinner D, Hicks SB, et al. (2012) Cystic fibrosis transmembrane conductance regulator modulation by the tobacco smoke toxin acrolein. Laryngoscope 122: 1193–1197.
2. Blount A, Zhang S, Chestnut M, Hixon B, Skinner D, et al. (2011) Transepithelial ion transport is suppressed in hypoxic sinonasal epithelium. Laryngoscope 121: 1929–1934.
3. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, et al. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106: 18825–18830.
4. Zhang S, Smith N, Schuster D, Azbell C, Sorscher EJ, et al. (2011) Quercetin increases cystic fibrosis transmembrane conductance regulator-mediated chloride secretion and ciliary beat frequency in sinonasal epithelium. Proc Natl Acad Sci U S A 106: 18825–18830.
5. Bhattacharyya N (2011) Incremental health care utilization and expenditures for chronic rhinosinusitis in the United States. Ann Otol Rhinol Laryngol 120: 423–427.
6. Azbell C, Zhang S, Skinner D, Fortenberry J, Sorscher EJ, et al. (2010) Hepes/pH stimulates cystic fibrosis transmembrane conductance regulator-mediated chloride secretion and ciliary beat frequency in sinonasal epithelium. Otolaryngol Head Neck Surg 143: 397–404.
7. Blount A, Zhang S, Chestnut M, Hixon B, Skinner D, et al. (2011) Transepithelial ion transport is suppressed in hypoxic sinonasal epithelium. Laryngoscope 121: 1929–1934.
8. Gliklich RE, Metson R (1995) The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg 113: 104–109.
9. Murphy MP, Fishman P, Short SO, Sullivan SD, Yuch B, et al. (2002) Health care utilization and cost among adults with chronic rhinosinusitis enrolled in a health maintenance organization. Otolaryngol Head Neck Surg 127: 367–376.
10. Mezher J, Saller R, Schapoval A, Brigoli R (2006) Systematic review of clinical data with BNO-101 (Sinupret) in the treatment of sinusitis. Forsch Komplementmed 13: 78–87.
11. http://abc.herbalgram.org/site/DocServer/Sinupret_clinOver.pdf?docID = 882 (Accessed 2010 March 2).
12. Illek B, Fischer H (1998) Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am J Physiol 275: L902–910.

13. Illek B, Fischer H, Machen TE (1996) Alternate stimulation of apical CFTR by genistein in epithelia. Am J Physiol 270: C263–273.

14. Illek B, Fischer H, Santos GF, Widdicombe JH, Machen TE, et al. (1995) cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am J Physiol 268: C386–893.

15. Virgin F, Zhang S, Schuster D, Zeng J, Zhang S, et al. (2010) The bioflavonoid compound, sinupret, stimulates transmembrane chloride transport in vitro and in vivo. Laryngoscope 120: 1031–1036.

16. Virgin FW, Azbell C, Schuster D, Sunde J, Zhang S, et al. (2010) Exposure to cigarette smoke condensate reduces calcium activated chloride channel transport in primary sinonasal epithelial cultures. Laryngoscope 120: 1465–1469.

17. Zhang S, Fortenberry JA, Cohen NA, Sorscher EJ, Woodworth BA (2009) Comparison of vectorial ion transport in primary murine airway and human sinonasal air-liquid interface cultures, models for studies of cystic fibrosis, and other airway diseases. Am J Rhinol Allergy 23: 149–152.

18. Cohen NA, Zhang S, Sharp DB, Tamashiro E, Chen B, et al. (2009) Cigarette smoke condensate inhibits transepithelial chloride transport and ciliary beat frequency. Laryngoscope 119: 2269–2274.

19. Woodworth BA, Tamashiro E, Bhargave G, Cohen NA, Palmer JN (2008) An in vitro model of Pseudomonas aeruginosa biofilms on viable airway epithelial cell monolayers. Am J Rhinol 22: 235–238.

20. Bhargave G, Woodworth BA, Xiaow G, Wolfe SG, Antunes MB, et al. (2009) Transient receptor potential vanilloid type 4 channel expression in chronic rhinosinusitis. Am J Rhinol 22: 7–12.

21. Woodworth BA, Antunes MB, Bhargave G, Xiaow G, Aguilar JL, et al. (2007) Murine nasal septa for respiratory epithelial air-liquid interface cultures. Biotechniques 43: 195–204.

22. Solomon GM, Frederic C, Zhang S, Gaggar A, Harris T, et al. (2013) IP-10 is a Potential Biomarker of Cystic Fibrosis Acute Pulmonary Exacerbations. PLoS One 8: e72390.

23. Lazrak A, Jurkiewanite A, Nas EC, Zhang S, Woodworth BA, et al. (2013) Inter-alpha-Inhibitor Blocks ENaC Activation and Decreases Nasal Potential Differences in DeltaF508 Mice. Am J Respir Cell Mol Biol.

24. Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, et al. (2008) TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 322: 590–594.

25. Pyle LC, Fulton JC, Slesane PA, Racker K, Mazur M, et al. (2009) Activation of CFTR by the Flavonoid Quercetin: Potential Use as a Biomarker of {Delta}F508 CFTR Rescue. Am J Respir Cell Mol Biol.

26. Ziemberry A, Boyce AT, Liang L, Prei-Peterdi J, Bell PD, et al. (2003) Sustained calcium entry through P2X nucleotide receptor channels in human airway epithelial cells. J Biol Chem 278: 13398–13406.

27. Schroeder BC, Cheng T, Jan YN, Jan LY (2008) Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 134: 1019–1029.

28. Simon JH, Stoner JA, Ammons BA, Wyatt TA (2003) All-digital image capture and whole-field analysis of ciliary beat frequency. J Microsc 211: 103–111.

29. http://www.bionoricausa.com/accordion-a/level-2 (Accessed 2010 March 24).

30. Schmolz M, Ottendorfer D, Marz RW, Schandl O, Wiedermann G, et al. (2001) Enhanced resistance to Sendai virus infection in DBA/2J mice with a botanical drug combination (Sinupret). Int Immunopharmacol 1: 1841–1848.

31. Chibanguza G, Marz R, Sterner W (1984) [The effectiveness and toxicity of a plant secretolytic agent and its component drugs]. Arzneimittelforschung 34: 32–36.

32. Richstein A, Mann W (1980) [Treatment of chronic sinusitis with Sinupret]. Ther Ggw 119: 1055–1060.

33. Guo R, Cantor PH, Ernst E (2006) Herbal medicines for the treatment of rhinosinusitis: a systematic review. Otolaryngol Head Neck Surg 135: 496–506.

34. Gyoromyoe K, Garmani E, Galley K, Rommens JM, Bear CE (2003) Non-CFTR chloride channels likely contribute to secretion in the murine small intestine. Pflugers Arch 443 Suppl 1: S103–108.

35. Salathe M (2007) Regulation of mammalian ciliary beating. Annu Rev Physiol 69: 401–422.

36. Zhang S, Blount AC, McNicholas CM, Skinner DF, Chestnut M, et al. (2013) Reveratrol enhances airway surface liquid depth in sinonasal epithelium by increasing cystic fibrosis transmembrane conductance regulator open probability. PLoS One 8: e72390.

37. Couper RT, Zhang S, Skinner D, Hicks SB, Sorscher EJ, et al. (2013) Comparison of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Ciliary Beat Frequency Activation by the CFTR Modulators Genistein, VRT-532, and UCCF-152 in Primary Sinonasal Epithelial Cultures. JAMA Otolaryngol Head Neck Surg 139: 822–827.